verteporfin


Also found in: Wikipedia.

verteporfin

 [ver″tĕ-por´fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathologic myopia; the agent is then activated by light of a specific wavelength in the presence of oxygen, and causes local damage to the neovascular endothelium followed by vessel occlusion; it is administered intravenously prior to irradiation of the lesion with light from a compatible laser.

ver·te·por·fin

(vĕr-tē-pōr'fin),
Photosensitizer agent used in photodynamic therapy to treat choroidal neovascularization secondary to age related macular degeneration.
References in periodicals archive ?
(5,10,11,12,13) Due to the multifactorial and complex mechanism of CSCR pathophysiology, several treatment options, such as conventional laser (CL) and verteporfin photodynamic therapy (PDT) have been tried, particularly in the treatment of the chronic type; however, CL was reported to have no significant effect on the final visual acuity or recurrence rate and to have toxic effect on the RPE and photoreceptors.
Ranibizumab versus verteporfin photodynamic therapy: Two-year results of the ANCHOR study.
A drug called Visudyne (verteporfin) is injected into a vein in the arm and is absorbed by the new growing blood vessels.
Kaiser et al., "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study," Ophthalmology, vol.
Triner et al., "Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1," Science Signaling, vol.
Cotelle, "Non-photoinduced biological properties of verteporfin," Current Medicinal Chemistry, vol.
PDT involved intravenously injecting a photosensitising drug called Verteporfin into the patient's circulation, where it became concentrated in areas of neovascularisation within the macula.
In the period leading up to 2005, intravitreal injection (CPT 67028) of medications slowly became popular as treatment modality for age-related macular degeneration after the Food and Drug Administration approval of verteporfin. From 2005 to 2009, intravitreal injection volume then increased dramatically due to the approval and use of pegaptanib, ranibizumab, and bevacizumab (Ramulu et al.
This approval is based on the results of the Phase III RADIANCE study, which indicated that treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy.
Focal laser photocoagulation (LP) and photodynamic therapy (PDT) with verteporfin have been used to treat CSCR.
Verteporfin, a hydrophobic photosensitizer, forms a soluble aggregate with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) (PMB).